CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; ...

AstraZeneca's five-year US$2.5 billion investment, announced on Friday, includes a new research-and-development center in Beijing and a research agreement with Harbour BioMed. The U.K. firm will also ...

Cambridge: Harbour BioMed, a global biopharmaceutical company has announced a global strategic collaboration with AstraZeneca ...

Under the terms of the agreements, AstraZeneca will obtain the option to license two preclinical immunology programs and will nominate further targets for Harbour BioMed to discover next ...

The investments come amid an ongoing investment fraud probe into AstraZeneca’s former China head Leon Wang—and despite ...

(RTTNews) - Harbour BioMed announced a global strategic collaboration with AstraZeneca to discover and develop multi-specific antibodies for immunology, oncology and beyond. Also, AstraZeneca will ...

The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to ...

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, announced a global strategic ...

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology.

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...